QT Imaging Releases Its Next Generation Breast Imaging Reconstruction Software

Key Terms

spatial resolution technical

Spatial resolution is a measure of how much fine detail an imaging system can show — essentially how close two objects can be and still appear as separate. For investors, higher spatial resolution usually means a product can detect smaller features or provide clearer diagnostic or mapping information, which can translate into better clinical outcomes, stronger regulatory acceptance, competitive advantage, and potentially higher sales; think of it like the difference between a standard photo and a high-definition close-up.

deconvolution technical

Deconvolution is a data-processing method that separates overlapping or blurred signals to recover the original components, like untangling mixed paint to reveal the individual colors that made the blend. For investors, it matters because it makes measurements from medical images, lab tests, or aggregated datasets clearer and more reliable, which strengthens clinical claims, regulatory evidence, and the quality of information used in valuation and risk decisions.

reflection imaging technical

Reflection imaging is a way to create pictures of the inside of the body by sending sound or light into tissue and collecting what bounces back, similar to how a bat uses echoes or how a mirror returns light. For investors, it matters because the quality, safety and cost of medical devices that rely on reflected signals determine clinical usefulness, regulatory approval, market adoption and revenue potential in diagnostic and treatment markets.

speed of sound medical

Speed of sound is the rate at which a pressure wave travels through a material or a medium, like how quickly a ripple spreads across water after you drop a stone. Investors should care because it shapes engineering limits, safety standards and certification hurdles in sectors such as aerospace, transportation and materials—affecting product performance, development costs and the market for technologies that must operate below, at or above that speed.

fibroglandular tissue medical

Fibroglandular tissue is the firm, fibrous and milk-producing part of the breast, as distinct from softer fat. Think of it as the structural framework and active machinery inside a fruit — denser, less transparent to X-rays and other imaging. For investors, its amount affects how well screening tools detect abnormalities, influences demand for advanced imaging and diagnostic services, and can shape regulatory, reimbursement and market opportunities in breast-health products and services.

quantitative biomarker medical

A quantitative biomarker is a measurable biological signal — like a blood level, imaging number, or genetic count — reported as a specific number that reflects disease presence, progression, or a treatment’s effect. For investors it matters because clear, repeatable numbers act like a thermometer for drug performance and patient selection, helping predict clinical success, regulatory approval chances, and commercial value, which in turn influences company risk and potential return.

attenuation medical

Attenuation is the reduction or weakening of something’s strength or effect over time or distance, such as a drug’s potency, a virus’s ability to cause disease, a signal’s clarity, or the impact of a business trend. For investors, attenuation matters because a smaller or waning effect can change a company’s future revenue, regulatory risk, or the value of an asset—think of it like turning down a volume knob: lower strength usually means less financial impact or lower urgency for action.

tissue characterization medical

Tissue characterization is the process of identifying the physical or biological properties of body tissue using images, sensors, or laboratory tests so doctors can tell healthy tissue from diseased or abnormal tissue. Think of it like analyzing the texture and color of fabric under a magnifying glass to spot defects. For investors, robust tissue characterization can drive clinical adoption, regulatory approval, and reimbursement for medical devices or diagnostics, directly affecting commercial value.

– New generation reconstruction software improves image quality and performance across challenging breast imaging cases –

NOVATO, Calif.--(BUSINESS WIRE)-- QT Imaging Holdings, Inc. (Nasdaq: QTI) (“QT Imaging” or the “Company”), a medical device company dedicated to transforming breast health management through innovative, radiation-free imaging technology, today announced its latest image reconstruction software update release, version 4.5.0. This next-generation software improves spatial resolution in reflection imaging by implementing optimized, spatially varying deconvolution during reflection image reconstruction, resulting in more accurate image representation while maintaining efficient processing times.

Version 4.5.0 also introduces enhanced reflection images generated through the fusion of speed of sound and reflection data, providing clinicians and researchers with improved visualization and more comprehensive tissue characterization information. These enhancements are designed to improve image interpretation and support comprehensive and reproducible analysis across a wide range of cases.

"The enhanced reflection images represent a meaningful improvement in image quality and usability. Combining reflection with speed of sound information provides additional insight that was not previously available from reflection imaging alone," said Dr. John Tentinger, President and Chief Executive Officer at Innovative Radiology, a radiology center in West Des Moines, Iowa, and a QT Imaging customer.

In addition, the 4.5.0 release includes improved image reconstruction for small breasts and the implementation of more accurate assessment of fibroglandular tissue composition in breasts with implants, addressing important clinical scenarios and expanding the software’s usability across a broader range of patient anatomies.

“Building on our multimodal imaging approach, we are advancing the development of attenuation as an additional quantitative biomarker, to complement speed of sound and reflection intensity. The integration of attenuation is expected to further enhance tissue characterization capabilities and provide clinicians and researchers with additional quantitative information for improved analysis and decision support," said Dr. James Wiskin, QT Imaging Fellow.

These advancements reflect QT Imaging’s continued focus on improving image quality, clinical reliability, and workflow efficiency, and represent another important step in the company’s ongoing development of advanced imaging software solutions.

About QT Imaging

QT Imaging Holdings, Inc. (Nasdaq: QTI) is a medical device company engaged in the research, development, and commercialization of innovative imaging systems using low frequency sound waves. QT Imaging Holdings, Inc. strives to improve global health outcomes. Its strategy is predicated upon the fact that medical imaging is critical to the detection, diagnosis, and treatment of disease and that it should be safe, affordable, accessible, and centered on the patient’s experience. For more information on QT Imaging Holdings, Inc., please visit the Company’s website at www.qtimaging.com and follow us on LinkedIn.

Breast Acoustic CT™ is a trademark of an affiliate of QT Imaging Holdings, Inc.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Exchange Act of 1934, as amended. Forward-looking statements generally are accompanied by words such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “plan,” “predict,” “potential,” “seem,” “seek,” “future,” “outlook,” and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding the updated reconstruction software, including its capabilities and advanced image reconstruction software performance of software enhancements, plans for QT Imaging, new product development and introduction, product sales growth and projected revenues, QT Imaging’s industry, future events, and other statements that are not historical facts. Forward-looking statements involve certain risks and uncertainties, and actual results may differ materially from those discussed in any such statement. These statements are based on various assumptions, whether or not identified herein, and on the current expectations of QT Imaging's management and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by you or any other investor as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond our control. These forward-looking statements are subject to a number of risks and uncertainties, including those relating to: the ability of the Company to sell and deploy the QT Imaging Breast Acoustic CT™ Scanner; the ability to extend product offerings into new areas or products; the ability to commercialize technology; unexpected occurrences that deter the full documentation and “bring to market” plan for products; trends and fluctuations in the industry; changes in demand and purchasing volume of customers; unpredictability of suppliers; the ability to attract and retain qualified personnel and the ability to move product sales to production levels; changes in domestic and foreign business, market, financial, political, and legal conditions; the uncertainty of projected financial information; delays caused by factors outside of our control; changes in our ability to successfully receive purchase orders and generate revenue under our existing contracts with partners and distributors; our ability to realize the benefits of the strategic partnerships; the identified material weakness in our internal controls over financial reporting (including the timeline to remediate the material weakness); the rollout of the business and the timing of expected business milestones; the effects of competition on our future business; our ability to obtain and access financing in the future; our ability to pay our debt obligations as they come due; and those factors discussed in the Company’s reports and other documents filed with the SEC, including under the heading “Risk Factors.” If any of these risks materialize or our assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that QT Imaging presently does not know or that QT Imaging currently believes are immaterial which could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements reflect QT Imaging's expectations, plans or forecasts of future events and views as of the date of this release. QT Imaging anticipates that subsequent events and developments will cause QT Imaging's assessments to change. However, while QT Imaging may elect to update these forward-looking statements at some point in the future, QT Imaging specifically disclaims any obligation to do so. Accordingly, undue reliance should not be placed upon the forward-looking statements.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260401748847/en/

Investors
Alliance Advisors IR
Jody Cain
Jcain@allianceadvisors.com
310-691-7107

Media
Alliance Advisors IR
Fatema Bhabrawala
fbhabrawala@allianceadvisors.com
647-620-5002

Source: QT Imaging Holdings, Inc.